Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew V Holt

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Ebiomedicine|April 12, 2017
Proof-of-Concept Workflow for Establishing Reference Intervals of Human Urine Proteome for Monitoring Physiological and Pathological ChangesWenchuan Leng, Xiaotian Ni, Changqing Sun, et al.
PNAS Nexus|September 25, 2024
Death-associated protein kinase 3 modulates migration and invasion of triple-negative breast cancer cellsJunkai Wang, Anh M Tran-Huynh, Beom-Jun Kim, et al.
Scientific Reports|January 14, 2021
Discovery of small molecules targeting the tandem tudor domain of the epigenetic factor UHRF1 using fragment-based ligand discoveryLyra Chang, James Campbell, Idris O Raji, et al.
Cancer Letters|May 30, 2026
NF1 loss in estrogen receptor-positive breast cancer induces osteoclast formation and immunosuppression to promote bone metastasisZifan Zhao, Ze-Yi Zheng, Jonathan T Lei, et al.
Molecular Cancer Therapeutics|May 23, 2024
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast CancerAnran Chen, Beom-Jun Kim, Aparna Mitra, et al.
Cancer Research Communications|July 28, 2023
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted TreatmentBeom-Jun Kim, Ze-Yi Zheng, Jonathan T Lei, et al.
Cell Reports. Medicine|August 1, 2025
Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancerMatthew V Holt, Yongchao Dou, Meggie N Young, et al.
Cell Reports. Medicine|June 6, 2025
Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkersEric J Jaehnig, Aranzazu Fernandez-Martinez, Tanmayi D Vashist, et al.
Journal of the American Society for Mass Spectrometry|August 20, 2020
Interlaboratory Study for Characterizing Monoclonal Antibodies by Top-Down and Middle-Down Mass SpectrometryKristina Srzentić, Luca Fornelli, Yury O Tsybin, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Ebiomedicine|April 12, 2017
Proof-of-Concept Workflow for Establishing Reference Intervals of Human Urine Proteome for Monitoring Physiological and Pathological ChangesWenchuan Leng, Xiaotian Ni, Changqing Sun, et al.
PNAS Nexus|September 25, 2024
Death-associated protein kinase 3 modulates migration and invasion of triple-negative breast cancer cellsJunkai Wang, Anh M Tran-Huynh, Beom-Jun Kim, et al.
Scientific Reports|January 14, 2021
Discovery of small molecules targeting the tandem tudor domain of the epigenetic factor UHRF1 using fragment-based ligand discoveryLyra Chang, James Campbell, Idris O Raji, et al.
Cancer Letters|May 30, 2026
NF1 loss in estrogen receptor-positive breast cancer induces osteoclast formation and immunosuppression to promote bone metastasisZifan Zhao, Ze-Yi Zheng, Jonathan T Lei, et al.
Molecular Cancer Therapeutics|May 23, 2024
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast CancerAnran Chen, Beom-Jun Kim, Aparna Mitra, et al.
Cancer Research Communications|July 28, 2023
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted TreatmentBeom-Jun Kim, Ze-Yi Zheng, Jonathan T Lei, et al.
Cell Reports. Medicine|August 1, 2025
Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancerMatthew V Holt, Yongchao Dou, Meggie N Young, et al.
Cell Reports. Medicine|June 6, 2025
Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkersEric J Jaehnig, Aranzazu Fernandez-Martinez, Tanmayi D Vashist, et al.
Journal of the American Society for Mass Spectrometry|August 20, 2020
Interlaboratory Study for Characterizing Monoclonal Antibodies by Top-Down and Middle-Down Mass SpectrometryKristina Srzentić, Luca Fornelli, Yury O Tsybin, et al.
Pageof 3